reflected by a reduced peak expiratory flow or FEV 1 (2) . Clinically useful biomarkers in asthma include sputum and blood eosinophils (3) , and results from several small studies looking at circadian variations in airway inflammation in asthma are conflicting (4) (5) (6) (7) (8) (9) . The sputum eosinophil percentage is used to guide management decisions in severe-asthma clinics (3), and therefore any diurnal variation in sputum eosinophilia could influence the management of patients.
We studied circadian variations in blood and sputum eosinophils in a cohort of patients with mild/moderate, atopic asthma compared with healthy control subjects. We then retrospectively compared sputum eosinophil counts from a severe-asthma clinic cohort in relation to the time of day of collection (morning vs. afternoon).
Methods
Ten healthy volunteers and 10 adults with mild/moderate, atopic asthma (Asthma Control Questionnaire 7, 0.9 [0.8-1.1]) who were on regular inhaled corticosteroids (equivalent to beclomethasone dipropionate 400 mg [400-650 mg]) were recruited for this study. The study protocol was approved by the Health Research Authority, National Research Ethics Service Committee of North West-Greater Manchester Central (REC 14/NW/1352). Written informed consent was obtained from all participants. Spirometry, blood eosinophils, induced sputum, and serum were collected during four visits, each 1 week apart, avoiding any potentiating effect of sputum induction on a subsequent sample. Visit 1 (V1) occurred at 16:00, V3 was at 10:00, and V4 was at 22:00. V2 involved an overnight stay, with sampling occurring at 16:00, 22:00, 04:00, and 10:00 the following morning.
Next, a circadian analysis was performed retrospectively on sputum eosinophil counts obtained from patients with severe asthma attending either a morning or afternoon clinic.
The median (interquartile range) is reported. Wilcoxon's test, the Mann-Whitney U test, and two-way ANOVA were used to analyze the data. A post hoc power analysis performed on the sputum eosinophil data resulted in a power of 81.86% for our observed effect size (1.057), and the minimum detectable effect size was 1.037 given 80% power. Power calculations were based on a Wilcoxon signed-rank test to detect the time-of-day difference in asthma patients. General linear modeling was used to analyze the severe-asthma cohort data and potential confounders. Chi-squared Fisher's exact test and the Pearson correlation coefficient were also used for analyses. P < 0.05 was considered statistically significant.
Results
Mild/moderate asthma. Healthy and asthma groups were matched for age (P = 0.63) and body mass index (P = 0.9). FEV 1 For patients with mild/moderate asthma and control subjects, the number of blood eosinophils showed a time-of-day difference, peaking at 04:00 (P , 0.01), with no difference between groups. Serum eotaxin did not vary by time of day or between groups.
Among patients with mild/moderate asthma, the sputum eosinophil percentages were significantly higher at 04:00 than at 16:00 (P , 0.05; Figure 1 ). There was no significant time-of-day variation in sputum eosinophils in the healthy group (P = 0.63). Sputum eosinophil percentages were significantly increased in the asthma group compared with the healthy group (P , 0.01). Sputum eotaxin was significantly increased at 04:00 compared with 16:00 in the asthma group (62. Severe asthma. A total of 131 patients attended the morning clinic and 193 attended the afternoon clinic. Groups were well matched for age (P = 0.11), body mass index (P = 0.25), FEV 1 % predicted (P = 0.85), smoking status (P = 0.3), serum total IgE (P = 0.23), fractional exhaled nitric oxide (P = 0.58), blood eosinophil count (P = 0.58), and treatment (intramuscular triamcinolone [P = 0.71], oral prednisolone [P = 0.31], or daily inhaled corticosteroids [beclomethasone dipropionate equivalent]; P = 0.31). Significantly more subjects in the morning group produced sputum spontaneously than by induction (77.1% vs. 62.1%; P , 0.005).
An analysis of the severe-asthma clinic cohort data revealed a significant time-of-day effect: sputum produced in the morning clinic contained a significantly higher percentage of sputum eosinophils than that produced in the afternoon clinic (morning sputum eosinophil percentage 1.25% [0.00-8.75%] vs. afternoon 0.5% [0.00-2.25%]; P = 0.008). A general linear modeling analysis showed that the time-of-day effect persisted even if patients were on high-dose steroids (P = 0.41) and was not affected by the type of sputum (spontaneous vs. induced; P = 0.54).
A significantly higher proportion of patients with severe asthma attending the morning clinic had positive sputum eosinophil counts (>3%) compared with those attending the afternoon clinic (37.4% vs. 21.6%; P = 0.002; Figure 2 ).
We found no difference in the proportion of cell counts that were classed as eosinophilic (>3% eosinophils) between spontaneously produced sputum and induced sputum (morning P = 0.6, afternoon P = 1). . Diurnal variation in blood and sputum eosinophils. Sputum eosinophil percentages increased significantly at 04:00 compared with 16:00 in patients with asthma (*P , 0.05, Mann-Whitney U test). This was not seen in the healthy group (P = 0.63). Sputum eosinophil percentages were significantly higher in patients with asthma compared with healthy control subjects (P , 0.01, two-way ANOVA). Shown are individual sputum eosinophil percentages (dots) and medians (bars) for healthy control subjects (gray) and patients with asthma (black). TCC = total cell count.
Discussion
This is the most comprehensive circadian study of biomarkers in asthma to date. We report, for the first time, a circadian variation in sputum eotaxin, peaking at 04:00. We confirmed that airway eosinophils showed a significant circadian rhythm in induced sputum from patients with mild/moderate asthma, with a peak influx at 04:00 coinciding with peak sputum eotaxin concentrations suggesting a chemotactic mechanism. We demonstrated that this was in antiphase with FEV 1 . In contrast to airway eosinophils, blood eosinophils oscillated diurnally in both healthy subjects and patients with asthma, suggesting that the physiological mechanism that controls the circadian variation in blood eosinophils is not upregulated in asthma. In support of this, there was no difference in serum eotaxin levels between the groups. We noticed a nadir in sputum eosinophil levels at 16:00, and although the difference was not statistically significant, sputum eosinophil levels appeared to be higher at 10:00, hinting at a possible time-of-day effect that would be relevant within a clinical working day. We postulated that a patient might produce a sputum sample with higher eosinophil counts while attending a morning clinic versus an afternoon clinic. In our retrospective evaluation, we identified that patients with severe asthma attending a morning clinic were almost twice as likely (37.4% vs. 21.6%) to have sputum eosinophilia (>3%) than those attending an afternoon clinic. These findings require confirmation in a prospective study; however, the implications are clinically important. In patients with severe asthma, increased sputum eosinophil counts are an indicator for treatment escalation (3). Based on our results, we propose that different clinical decisions could be made based on whether the patient is allocated a morning or afternoon appointment. n Reduced lung BMPR2 (bone morphogenetic protein receptor type 2) expression and female predominance are two major features of most pulmonary arterial hypertension (PAH) subtypes (1). In addition, germline mutations in BMPR2 are present in more than 75% of patients with heritable PAH, and about 20% of patients with idiopathic PAH (2). However, only 14% of males, compared with 42% of females, who harbor BMPR2 mutations develop PAH (3).
There is a growing body of molecular and in vivo work supporting the concept that sex and BMPR2 are intimately related to each other, to PAH pathogenesis, and perhaps to right ventricular adaptation. For example, estrogen receptor a binds to the BMPR2 promoter in Cos-7 cells, leading to decreased expression and signaling of BMPR-II, whereas female human pulmonary artery smooth muscle cells exhibit estrogen-driven suppression of BMPR-II signaling (4, 5); however, estrogen signaling appears to support right ventricular response to stress (6) . Although likely relevant, a focus only on sex hormones ignores an obvious difference between females and males: the sex chromosomes (XX vs. XY). Importantly, recently in the Journal, Umar and colleagues demonstrated a protective effect of the Y chromosome in murine hypoxia-induced pulmonary hypertension (7) . We explored the hypothesis that the higher female incidence in PAH is driven in part by factors specific to the Y chromosome that enhance BMPR2 expression, with a focus on the transcription factor SRY (sex-determining region Y).
To start, we analyzed BMPR2 proximal regulator sequences using the transcription element search system and transcription factor database (http://www.gene-regulation.com). These analyses predicted BMPR2 upstream regulatory regions had at least five SRY binding sites. This suggested to us that SRY may regulate BMPR2 mRNA expression.
We next evaluated SRY expression in different cell types and found that SRY expression was low in multiple different male lung vascular cell lines but high in dermal fibroblast cell lines from multiple control patients and patients with PAH (data not shown). We then sought to determine whether SRY regulates native BMPR2 expression. We used RNA interference to knockdown SRY expression in fibroblasts from a male patient with PAH. We found that reducing SRY expression resulted in decreased BMPR2 mRNA and protein expression ( Figure 1A) . Although Smad 1/5/8 protein expression was not demonstratively reduced (data not shown), the breadth of canonical and noncanonical BMPR2 signaling was not assessed. We then used a SRY expression construct to overexpress SRY in a female HEK293 cell line (which does not express SRY). We found that SRY overexpression resulted in z20% increased BMPR2 expression compared with control ( Figure 1B) .
We next investigated whether BMPR2 is regulated by SRY in a dose-dependent manner. A BMPR2 promoter expression construct pGL3-BMPR2-Luciferase (containing the predicted SRY binding sites) was used in a cotransfection assay with a varying amount of SRY expression construct. We found that an increased 
